Form 8-K - Current report:
SEC Accession No. 0001493152-24-052755
Filing Date
2024-12-31
Accepted
2024-12-31 17:21:41
Documents
13
Period of Report
2024-12-31
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 37272
  Complete submission text file 0001493152-24-052755.txt   214611

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE awh-20241231.xsd EX-101.SCH 3012
3 XBRL LABEL FILE awh-20241231_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE awh-20241231_pre.xml EX-101.PRE 24164
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3832
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 241593810
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)